Abeona Therapeutics Inc. (LON:0H7R)
London
· Delayed Price · Currency is GBP · Price in USD 5.34
-0.13 (-2.34%)
At close: May 9, 2025
Abeona Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
136
Market Cap
192.35M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 42.56B |
| GSK plc | 31.53B |
| Haleon | 11.23B |
| Smith & Nephew | 4.64B |
| ConvaTec Group | 1.83B |
| Hikma Pharmaceuticals | 2.50B |
| HUTCHMED (China) | 503.39M |
| Genus | 671.60M |
Abeona Therapeutics News
- 9 days ago - Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
- 9 days ago - Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
- 9 days ago - Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
- 10 days ago - Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy - Benzinga
- 11 days ago - Abeona spikes on FDA nod for gene therapy - Seeking Alpha
- 11 days ago - US FDA approves Abeona's skin disorder therapy - Reuters
- 11 days ago - U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 12 days ago - Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + - Seeking Alpha